US FDA Should Offer Formal Declaration Of Orphan Drug Flexibility, Attorney Says

 
• By Derrick Gingery
  
FDAEntrance_1200x675
The FDA may not be adequately communicating its rare disease flexibility policy to sponsors in official documents. • Source: File photo
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Approval Standards

More from Pathways & Standards